On November 19, 2025, Wilson Sonsini obtained a significant milestone for Azurity Pharmaceuticals, with the Patent Trial and Appeal Board (PTAB) instituting inter partes review in all five petitions the firm filed on Azurity’s behalf. The petitions challenge methods and compositions for treating chemotherapy-induced nausea and vomiting. The Board’s institution decisions found a reasonable likelihood that Azurity will prevail on at least one challenged claim in each proceeding and authorized full trials on the grounds raised. The Board’s decisions are a notable milestone in the current PTAB environment, where institution rates have tightened significantly. Three Administrative Patent Judges independently concluded the challenges were reasonably likely to succeed, and the cases will now proceed to the yearlong trial phase. 

“Securing institution in all five petitions—after surviving the Director’s discretionary review—marks an important step for Azurity,” said Wilson Sonsini partner Jad Mills. “The PTAB agreed that we are reasonably likely to succeed, and we look forward to pressing forward with these challenges.” 

The Wilson Sonsini team representing Azurity includes Richard Torczon, Jad Mills, Wendy Devine, Michael Rosato, Natalie Morgan, Garrett Potter, and Patrick Medley.